Cita APA

Liu, D., Offin, M., Harnicar, S., Li, B. T., & Drilon, A. (2018). Entrectinib: An orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors. Ther Clin Risk Manag.

Chicago Style Citation

Liu, Dazhi, Michael Offin, Stephen Harnicar, Bob T. Li, i Alexander Drilon. "Entrectinib: An Orally Available, Selective Tyrosine Kinase Inhibitor for the Treatment of NTRK, ROS1, and ALK Fusion-positive Solid Tumors." Ther Clin Risk Manag 2018.

Cita MLA

Liu, Dazhi, et al. "Entrectinib: An Orally Available, Selective Tyrosine Kinase Inhibitor for the Treatment of NTRK, ROS1, and ALK Fusion-positive Solid Tumors." Ther Clin Risk Manag 2018.